Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,737 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure,Chronic Clear all
Completed Not applicable Interventional

Providing Resources to Enhance African American Patients' Readiness to Make Decisions About Kidney Disease (PREPARED) Study

NCT01439516
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Interventions
Information
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 21, 2026, 5:05 PM EDT
Active, not recruiting Not applicable Interventional

Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)

NCT06189807
View directory record Official record
Conditions
CKD, Chronic Kidney Diseases
Interventions
Decision aid, Standard handout
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 21, 2026, 5:05 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

NCT00442871
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Not applicable Interventional

Community-Based Screening for Chronic Kidney Disease

NCT07747363
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
outpatient clinic kidney-protective care
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271
View directory record Official record
Conditions
Sickle Cell Disease, Kidney Injury, Kidney Diseases, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 21, 2026, 5:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function

NCT00568009
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
SLV320
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
10
States / cities
Whittier, California • Largo, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.

NCT04409132
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)

NCT03259087
View directory record Official record
Conditions
Renal Impairment
Interventions
MK-3866
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 21, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses

NCT04392206
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Adipose Derived Mesenchymal Stem Cells
Drug
Lead sponsor
Houssam Farres, M.D.
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Not applicable Interventional

PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum

NCT01319578
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
K2CG chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Oct 21, 2026, 5:05 PM EDT
Recruiting No phase listed Observational

PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

NCT06422871
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis Access Failure
Interventions
HeRO® Graft System or Super HeRO® System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Sarasota, Florida • Raleigh, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis

NCT00242164
View directory record Official record
Conditions
Chronic Kidney Disease, Arrhythmia
Interventions
Dialysate Magnesium (Concentration)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 21, 2026, 5:05 PM EDT
Enrolling by invitation No phase listed Observational

Blood Volume Monitoring Via Critline in Volume Overload: Hospitalization and Readmission

NCT07866872
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Volume Overload
Interventions
Relative Blood Volume Monitoring (RBVM)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

NCT00859131
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rabbit Antithymocyte globulin, Daclizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 21, 2026, 5:05 PM EDT
Completed No phase listed Observational

Barriers to Peritoneal Dialysis Selection

NCT01517841
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

NCT03814005
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 21, 2026, 5:05 PM EDT
Not listed Phase 2 Interventional

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

NCT00358046
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency
Interventions
ILY101
Drug
Lead sponsor
Ilypsa
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Mountain View, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 21, 2026, 5:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

NCT02230202
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Flow-mediated dilation, single blood draw
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 21, 2026, 5:05 PM EDT
Completed Not applicable Interventional

The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis

NCT03943212
View directory record Official record
Conditions
ESRD, Fatigue, Hemodialysis-Induced Symptom
Interventions
Blood Flow Rate Reduction, Control
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years to 89 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Capitola, California • Daly City, California • Gilroy, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 21, 2026, 5:05 PM EDT
Terminated Phase 4 Interventional Results available

Artegraft Versus Propaten Dialysis Grafts

NCT02099344
View directory record Official record
Conditions
ESRD, Renal Failure
Interventions
Artegraft, Propaten
Device
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 21, 2026, 5:05 PM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 21, 2026, 5:05 PM EDT
Completed No phase listed Observational Results available

Safe Kidney Care Cohort Study

NCT01407367
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2019 · Synced Oct 21, 2026, 5:05 PM EDT